Friday, April 16, 2021

Germany suspends use of Oxford vaccine in children under 60 – Prime Time Zone

Facebook
Twitter
Pinterest
WhatsApp
Telegram

Must Read

The country recorded 31 cases of thrombosis in people who had recently received the immunizer, including nine deaths

EFE / EPA / CLEMENS BILAN / POOL“Fortunately, we have enough vaccines to be able to make that decision,” commented Prime Minister Angela Merkel

A Germany announced on Tuesday, 30, that it will manage the vaccine against Covid-19 developed by AstraZeneca in partnership with Oxford University preferably in people over 60 years of age. The measure is related to the 31 cases of thrombosis in people who received the immunizer in the country. According to the Paul-Ehrlich Institute, of the nine fatal victims, only two were men, one 36 and another 57 years old. The other seven were women aged between 20 and 63 years. The Robert Koch Institute has warned that these side effects can manifest between four and 16 days after a dose is inoculated, especially in people under the age of 60. As 2.7 million people have already received the Oxford vaccine in Germany, the Permanent Commission for Vaccination recognized that the cases are rare, but argued that, because they are serious, they deserve to be treated with caution. “Fortunately, we have enough vaccines to be able to make that decision,” commented Prime Minister Angela Merkel on the matter. Although the European Medicines Agency (EMA) has ruled out the link between the Oxford vaccine and cases of thrombosis, the use of the immunizer was already suspended in several states in Germany.

Canada

The health authorities of the Canada recommended on Monday, 29, the suspension of the use of the Oxford vaccine in people under 55 years of age. Although 500,000 doses of the immunizer have already been administered in the country without a significant amount of adverse reactions, Canada’s National Advisory Committee on Immunization is concerned about the cases of thrombosis reported in foreign nations, especially in Europe. For this reason, the government will ask the manufacturer to carry out a detailed assessment of the benefits and risks of the immunizer by age and sex in the Canadian domestic context. Health officials stressed that the data provided by pharmaceutical companies will determine whether additional regulatory action is needed or not.

Facebook
Twitter
Pinterest
WhatsApp
Telegram

Latest News

Wearing a mask in outdoor environments will no longer be mandatory in Israel – Prime Time Zone

With more than half of the population vaccinated against Covid-19, the country decided to suspend the measure that was...

More Articles Like This

spot_img